BioSpace News Archive

DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, announces the appointment of industry veteran Jack Kenny to its board of directors.

ValGenesis, Inc. announced that a Japanese multinational biopharmaceutical company selected ValGenesis iRisk for implementing the ICH Q14 framework on Process Analytical Technology analytical methods across its global manufacturing sites.

Cencora, Inc. announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024.

Fractyl Health, Inc. announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.

NANO-X IMAGING LTD and its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., announced that early findings from the ADOPT study, which uses a Nanox.AI artificial intelligence solution, HealthVCF, to review routine CT scans, have identified up to six times more patients with vertebral compression fracture than the national average at NHS hospitals in the UK, which include University of Oxford and other healthcare centers.

Lamassu Bio Inc. has been awarded a grant from the National Institutes of Health and National Cancer Institute for the development of their groundbreaking treatment for p53 wild-type sarcomas.

The Leukemia & Lymphoma Society announced that BeiGene, Ltd., a global oncology company, has signed a three-year partnership to join LLS as the National Presenting Sponsor of Survivorship & Hope at Light The Night philanthropic events across the U.S. helping to support blood cancer patients and families who have emerged from the darkness of cancer.

Arctic Therapeutics today announced approval by the European Medicines Agency (EMA) for initiation of the first clinical trial evaluating AT-001 (Nacuity’s NPI-001) for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA) in Iceland.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the publication, in Cardiovascular Diabetology, of an independent, peer-reviewed study utilizing its MyoVista® proprietary technology.

T2 Biosystems, Inc. today announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on the Nasdaq Stock Market.